Stockreport

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile [Yahoo! Finance]

Palisade Bio, Inc.  (PALI) 
PDF TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target. The firm expects limited near-term activity i [Read more]